NasdaqCM - Nasdaq Real Time Price USD
Intensity Therapeutics, Inc. (INTS)
At close: November 21 at 4:00 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
16,734.0000
8,319.0000
7,550.0000
7,996.4990
6,223.2460
Operating Income
-16,734.0000
-8,319.0000
-7,550.0000
-7,996.4990
-6,223.2460
Net Non Operating Interest Income Expense
462.0000
19.0000
-80.0000
-14.1580
74.0090
Other Income Expense
13.0000
-2,238.0000
48.0000
115.5130
118.7570
Pretax Income
-16,259.0000
-10,538.0000
-7,582.0000
-7,895.1440
-6,030.4800
Net Income Common Stockholders
-16,259.0000
-11,862.0000
-7,582.0000
-7,895.6000
-6,030.4800
Diluted NI Available to Com Stockholders
-16,259.0000
-11,862.0000
-7,582.0000
-7,895.6000
-6,030.4800
Basic EPS
-1.07
-1.38
-2.19
-0.60
-0.33
Diluted EPS
-1.07
-1.38
-2.19
-0.60
-0.33
Basic Average Shares
13,748.0800
8,616.3240
3,463.6350
13,099.3770
18,268.3470
Diluted Average Shares
13,748.0800
8,616.3240
13,099.3770
13,099.3770
18,268.3470
Total Operating Income as Reported
-16,734.0000
-8,319.0000
-7,550.0000
-8,013.7220
-6,223.2460
Rent Expense Supplemental
--
--
142.0000
153.0000
--
Total Expenses
16,734.0000
8,319.0000
7,550.0000
7,996.4990
6,223.2460
Net Income from Continuing & Discontinued Operation
-16,259.0000
-10,538.0000
-7,582.0000
-7,895.6000
-6,030.4800
Normalized Income
-16,259.0000
-8,276.0000
-7,582.0000
-7,895.6000
-6,030.4800
Interest Income
462.0000
324.0000
2.0000
2.6090
74.0090
Interest Expense
--
305.0000
82.0000
16.7670
--
Net Interest Income
462.0000
19.0000
-80.0000
-14.1580
74.0090
EBIT
-16,259.0000
-10,233.0000
-7,500.0000
-7,878.3770
-6,223.2460
EBITDA
-16,259.0000
-10,233.0000
-7,500.0000
-7,878.3770
-6,223.2460
Net Income from Continuing Operation Net Minority Interest
-16,259.0000
-10,538.0000
-7,582.0000
-7,895.6000
-6,030.4800
Total Unusual Items Excluding Goodwill
--
-2,262.0000
--
--
--
Total Unusual Items
--
-2,262.0000
--
--
--
Normalized EBITDA
-16,259.0000
-7,971.0000
-7,500.0000
-7,878.3770
-6,223.2460
12/31/2020 - 6/30/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PRTG Portage Biotech Inc.
4.5200
-1.09%
INKT MiNK Therapeutics, Inc.
0.6900
-2.80%
DWTX Dogwood Therapeutics, Inc.
2.7100
+11.52%
ESLAW Estrella Immunopharma, Inc.
0.0920
0.00%
OKUR OnKure Therapeutics, Inc.
15.99
-0.06%
MBXBF Microbix Biosystems Inc.
0.2190
0.00%
TNFA TNF Pharmaceuticals, Inc.
1.3600
+12.40%
NRBO NeuroBo Pharmaceuticals, Inc.
2.3500
-0.42%
ACHFF Arch Biopartners Inc.
1.3800
+1.47%
RLYB Rallybio Corporation
0.9886
-0.55%